Future Market Trends of Parkinson’s Disease Market Till 2021

1
Frontier Pharma Parkinsons Disease -
Identifying and Commercializing First-in-Class
Innovation
Published on - 01 January, 2016 Number of
pages 95 Single User Price 6995
The current market offers a number of anti-PD
treatment options which provide symptomatic
relief. Levodopa is currently the gold standard
therapy, with other drug classes including
dopamine agonists and Monoamine Oxidase B (MAO-B)
inhibitors also used to treat early and advanced
cases.
2
Parkinsons Disease (PD) is the second most
common neurodegenerative disease after
Alzheimers disease, affecting around 7.4 million
people worldwide. It is caused by the progressive
loss of dopamine-producing neurons in the
substantia nigra within the basal ganglia. The
main motor symptoms are tremors, bradykinesia and
rigidity, although symptoms vary between
individuals. As the disease progresses to more
advanced stages, increasing symptoms and
complications develop, which can cause severe
disability in patients. With no current
treatment showing effectiveness in delaying the
course of the disease, PD remains incurable. The
high unmet need for a disease-modifying therapy
is reflected in the pipeline, where a high
proportion of early-stage first-in-class programs
target the potential pathogenic mechanisms
underlying neurodegeneration. The current market
offers a number of anti-PD treatment options
which provide symptomatic relief. Levodopa is
currently the gold standard therapy, with other
drug classes including dopamine agonists and
Monoamine Oxidase B (MAO-B) inhibitors also used
to treat early and advanced cases.
Click Here To Check Complete Report
3
Scope of the Report PD is a crowded market
with many neuromodulatory drug classes available.
However, a disease-modifying therapy with
neuroprotective effects is yet to be
developed.1. What are the primary mechanisms
that are thought to contribute to neuronal
death?2. What are the major barriers facing the
development of investigational neuroprotective
candidates?Analysis reveals a high level of
innovation and diversity in the pipeline, with
121 first-in-class programs acting on 57 unique
molecular targets.Neuromodulatory targets remain
the dominant target family, particularly in the
late-stage pipeline.1. What are the
first-in-class families with a significant
presence?2. How well do they align with the
underlying pathways governing neuronal death in
PD?Some of the first-in-class targets have a
potentially stronger chance of being translated
into novel treatments for PD.1. What is the
scientific rationale behind these targets? How do
they perform in Preclinical studies?2. What are
the commonly used disease models and the
parameters measuring neuroprotective effects in
PD animal studies?
Download Sample Brochure
4

• Reasons to BuyThis report will allow you to -
• Understand the current clinical and commercial
  landscape by considering the proposed pathogenic
  processes underlying PD neurodegeneration,
  diagnosis, prognosis, and the available treatment
  options and their usage in early and advanced PD.
• Visualize the composition of the PD market to
  highlight the current unmet needs in order to
  gain a competitive understanding of the key
  opportunities.
• Analyze the PD pipeline and stratify by stage of
  development, molecule type, and molecular target
  - the diversity of molecular targets in the
  pipeline is extremely encouraging due to the
  multifaceted nature of PD.
• Assess the therapeutic potential of
  first-in-class targets using a proprietary matrix
  that assesses and ranks first-in-class products
  according to clinical potential.
• Target the most promising and innovative PD
  products for early-stage investment by analyzing
  trends in licensing and co-development deals and
  accessing a curated list of first-in-class
  therapies potentially open to deal-making
  opportunities.

Make an Inquiry Before Buying
5
Frontier Pharma Parkinsons Disease -
Identifying and Commercializing First-in-Class
Innovation
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
Frontier Pharma Parkinsons Disease -
Identifying and Commercializing First-in-Class
Innovation and future opportunities are provided
in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Parkinsons Disease
Market Report